elderly underactive bladder symptoms needed to be reported

Mirabegron Safe, Effective for Overactive Bladder in the Elderly

Mirabegron is a safe and effective treatment for overactive bladder (OAB) in older patients, a researcher reported at the International Continence Society’s 2018 annual meeting. Adrian Wagg, MB, BS, of the University of Alberta in Edmonton, presented findings from a 12-week phase 4 prospective, randomized, placebo-controlled trial that enrolled 888 patients older than 65 years who had OAB symptoms for 3 months or more. The mean age of the patients was about 72 years. The proportion of patients older than 75 years was 28% among mirabegron and placebo recipients. Read more.

Source: Renal and Urology News, August 31, 2018

Most Transient SUI After HoLEP Resolves Within 6 Weeks

Most men who experience transient stress urinary incontinence (SUI) following holmium laser enucleation of the prostate (HoLEP) recover full bladder control within the first 6 weeks after the procedure, according to study findings presented at the International Continence Society’s 2018 annual meeting. In addition, the study identified prostate size larger than 100 g and catheter dependency prior to HoLEP, and longer operative time as risk factors for transient SUI. A retrospective review of 515 patients who underwent HoLEP showed that 53 (10.3%) experienced transient SUI, Jenny Guo, BS, and colleagues at Sidney Kimmel Medical College at Thomas Jefferson University in Philadelphia, reported. Transient SUI resolved within the first 6 weeks post-operatively in 47 (88.6%) of these patients and within 6 week to 3 months in 6 patients (11.3%). Read more.

Source: Renal and Urology News, August 30, 2018

ICS 2018: Atlantic Therapeutics Exhibit New Data Demonstrating Comparable Efficacy, Increased Tolerability and Reduced Infection Risk of its Non-invasive Device Innovo® in Treating Stress Urinary Incontinence

Atlantic Therapeutics, a global manufacturer of innovative, garment-based pelvic floor muscle strengthening and nerve stimulation products, exhibits data highlighting comparable safety and efficacy of its INNOVO^®therapy, an externally worn electrical muscle stimulation device for the treatment of stress urinary incontinence, with greatly reduced risk of infection and improved user tolerability over existing intravaginal probe devices¹. Presented as a poster at the 48th Annual Meeting of the International Continence Society, the data was the result of an FDA designed clinical trial, with patients whose condition had not improved using pelvic floor muscle training. Supporting Atlantic Therapeutics’ FDA approval via the De Novo route for INNOVO^®. Designed for at home use and worn as a close-fitting pair of shorts, INNOVO^® was compared with an existing FDA approved intravaginal stimulation product as control. Read more.

Source: PRNewswire, August 28, 2018

TARIS Announces Positive Topline Data for TAR-302 in Patients with Idiopathic Overactive Bladder

TARIS, a biopharmaceutical company developing transformational therapies to treat people with debilitating urological disorders, today announced positive preliminary safety and efficacy data from its clinical study of TAR-302 for the treatment of patients with idiopathic overactive bladder (OAB) refractory to oral therapy. Subjects in the Phase 1b study received a single TAR-302 system, which provides continuous local dosing of the approved antimuscarinic agent trospium into the bladder. Subjects who were experiencing an average of more than five daily urge incontinence episodes demonstrated a reduction in mean daily episodes of 75% following dosing for 42 days (p=0.0049). Based on the unmet need in this disease state and the efficacy demonstrated in this study on established endpoints, TARIS plans to rapidly advance this program into later stage trials. “The results of this study suggest TAR-302 may come to represent an innovative new approach to treating overactive bladder,” said Michael J. Kennelly, M.D., FACS, Professor of Urology at Carolinas Medical Center, Medical Director of the Charlotte Continence Center and Women’s Center of Pelvic Heath, and Principal Investigator of the TAR-302 clinical studies. “There is a substantial need for alternative options in the management of OAB when patients fail oral therapies. The compelling efficacy observed to date with TAR-302, in the absence of side-effects, represents a potentially significant advance in the development of improved therapies for these patients.” Read more.

Source: PRNewswire, August 28, 2018

Time to Tackle ‘Taboo’ Over Continence Issues, Warn Charities

The 10 charities, including Alzheimer’s Society, Age UK, Marie Curie, warned that the taboo around the topic forces those affected to struggle in silence and more research is needed. As a result, the organisations held a workshop where common problems and solutions for incontinence issues were discussed by patients, carers, researchers and clinicians. Others involved include Parkinson’s UK, Guts UK, the Urology Foundation, Devices for Dignity, the National Institute for Health Research, and the James Lind Alliance. A report based on the meeting – titled My bladder and bowel own my life and published today – recommends tackling the stigma and funding research into the issue. Read more.

Source: Nursing Times, August 22, 2018

Magnetic Stimulation Restores Bladder Control in Paralyzed Men

Patients with spinal cord injuries report that in addition to paralysis the lack of bladder control is one of the most troubling issues. At University of California Los Angeles, researchers have shown that they were able to restore significant bladder control to five men that suffered through spinal cord injuries years prior to treatment. The researchers used transcutaneous magnetic spinal cord stimulation as their technique, delivering pulses of focused magnetic fields to the site of the injuries. Similar technology was just cleared in the United States to treat obsessive compulsive disorder. Read more.

Source: Medgadget, August 22, 2018

PeriCoach® Real-World Data Analysis Reveals Statistically and Clinically Significant Reduction in Incontinence Symptoms Within 3 Weeks

Analysis of PeriCoach real-world data conducted by an independent biostatistician reveals significant improvements in pelvic floor strength in five weeks, and reduction in urine volume and leakage episodes in only three weeks. The post-approval, all-comers observational study, reviewed women using the version 3 PeriCoach system. PeriCoach version 3, released May 2017, comprises a state-of-the-art biofeedback system combined with a structured treatment programme. The market-leading features include real-time technique feedback to assist with proper pelvic floor muscle contraction, and force-sensors that measure the muscles that matter. During initial set-up, new users are invited to participate in a structured exercise regime and record urinary habits in the app-based bladder diary. The PeriCoach “8 Week Challenge” provides users with reminders to exercise a minimum of five sessions a week, enter information into the bladder diary three days a week, and respond to a quality of life survey at onset, four and eight weeks. Read more.

Source: PRNewswire, August 21, 2018

Screening for Urinary Incontinence in Women: A Recommendation

Recommendation on screening for urinary incontinence in women by the Women’s Preventive Services Initiative (WPSI), a national coalition of women’s health professional organizations and patient representatives. The WPSI’s recommendations are intended to guide clinical practice and coverage of services for the Health Resources and Services Administration and other stakeholders. The target audience for this recommendation includes all clinicians providing preventive health care for women, particularly in primary care settings. This recommendation applies to women of all ages, as well as adolescents. Read more.

Source: Annals of Internal Medicine, August 14, 2018

Nearly 1 in 2 Women Aged 45+ Report Urinary Incontinence

Urinary incontinence occurs in nearly 1 in 2 women aged 45 years and older, a new study suggests. The study examined survey results from 143,096 women at baseline (2006–2009) and 59,060 women who participated in a follow-up survey (2012–2015). The prevalence of urinary leakage reported in these surveys was 44% and 44.6%, respectively, Kristine Concepcion, MD, MPH, of Family Planning NSW Ashfield in New South Wales, Australia, and colleagues reported in Neurourology and Urodynamics. Read more.

Source: Renal and Urology News, August 2, 2018

FDA Warns About ‘Deceptive’ Vaginal Rejuvenation Claims

Procedures marketed to improve a woman’s “intimate health” using lasers or ultrasound are not only unapproved, but are also causing burns and other painful damage, the Food and Drug Administration said Monday. The FDA has warned seven companies that are promoting their devices for these procedures, and issued a general alert for patients and doctors. The agency has also warned the public against asking for such procedures. The laser and ultrasound equipment used in these unapproved procedures has FDA approval for removing genital warts, other growths and in operations such as hysterectomies. But they have not been shown to tighten up muscles, increase sexual pleasure or relieve pain during intercourse, the FDA said. Read more.

Source: NBC News, July 30, 2018